|
(a)
|
(b)
|
(c)
|
(d)
|
(e)
|
(f)
|
(g)
|
|---|
|
Phrase 1 (containing the Arabic numerical variant)
|
Number of patients with Phrase 1 only
|
% of patients missed if searching only for Phrase 1
|
Number of patients with both Phrase 1 and Phrase 2
|
Number of patients with Phrase 2 only
|
% of patients missed if searching only for Phrase 2
|
Phrase 2 (containing the Roman numerical variant)
|
|---|
|
citrullinemia type 1
|
2
|
25.0
|
1
|
1
|
50.0
|
citrullinemia type I
|
|
type 2 diabetes mellitus
|
43,777
|
10.5
|
7919
|
6053
|
75.8b
|
type II diabetes mellitus
|
|
type 1 neurofibromatosis
|
181
|
24.5
|
56
|
77
|
57.6b
|
type I neurofibromatosis
|
|
Tanner Stage 3
|
7639
|
57.8b
|
1373
|
12,367
|
35.7
|
Tanner Stage III
|
|
grade 3 anaplastic astrocytoma
|
42
|
36.7
|
27
|
40
|
38.5
|
grade III anaplastic astrocytoma
|
|
stage 3 chronic kidney disease
|
615
|
67.4b
|
446
|
2190
|
18.9
|
stage III chronic kidney disease
|
|
factor 9 deficiency
|
14
|
68.1b
|
51
|
139
|
6.9
|
factor IX deficiency
|
|
class 3 malocclusion
|
135
|
81.2b
|
115
|
1079
|
10.2
|
class III malocclusion
|
|
phase 1 clinical trial
|
320
|
66.5b
|
263
|
1158
|
18.4
|
phase I clinical trial
|
|
Mallampati score: 4
|
121
|
27.8
|
1
|
47
|
71.6b
|
Mallampati score: IV
|
- aReesults from a cohort identification exercise for 10 diagnoses and clinical findings in the clinical notes, including counts of the number of patients identified by searching for phrases containing either the Arabic or Roman numeral variants, or both. The percentage of patients potentially missed by searching for only one of the variants is displayed
- b Cells with percentages > 50%
